No Association Between the Angiotensin-Converting-Enzyme Gene Insertion/Deletion Polymorphism and the Occurrence of Macroangiopathy in Patients with Diabetes Mellitus Type 2

Abstract

Previous studies have reported an association between the ACE-I/D-polymorphism and coronary heart disease (CHD) in patients with diabetes mellitus. However, ACE inhibitor treatment, which could have compensated for negative effects of the D/D form of the ACE gene polymorphism, was not considered in the studies. We investigated the influence of the ACE-I/D polymorphism and the ACE inhibitor treatment in patients with diabetes mellitus on the occurrence of CHD by multiple-regression analysis. Distribution of the ACE gene I/D-polymorphism was investigated in 691 patients with diabetes mellitus prospectively characterised for the presence/absence of coronary heart disease. The distribution of DD; ID; II genotypes was 105 vs. 202 vs. 102 (25.7 % vs. 49.4 % vs. 24.9) in the CHD⁺ group and 55 vs. 160 vs. 67 (19.5 % vs. 56.7 % vs. 23.8 %) in the CHD^- group, respectively (p = 0.1). A multiple logistic regression analysis introducing the typical risk factors for CHD (age, gender, smoking, BMI > 26 kg/m², LDL elevation, HbA1c > 7 %) could not identify the ACE gene I/D-polymorphism as an independent risk factor for CHD (p = 0.87). Our data therefore suggest that the ACE gene I/D polymorphism is not associated with the occurrence of diabetic macroangiopathy in patients with or without treatment of ACE inhibitors.

Key words

Diabetes - Genetics - Complications of Diabetes

References

• 1 Seaquist E R, Goetz F C, Rich S, Barbosa J. Familial clustering of diabetic kidney disease: Evidence for genetic susceptibility to diabetic nephropathy.  N Engl J Med. 1989;  320 1161-1165
• 2 Pettitt D J, Saad M F, Bennett P H, Nelson R G, Knowler W C. Familial predisposition to renal disease in two generations of Pima indians with type II (non-insulin dependent) diabetes mellitus.  Diabetologia. 1990;  33 438-443
• 3 Ballard D J, Humphrey L L, Melton 3rd L J. Epidemiology of persistent proteinuria in typ II diabetes mellitus. Population based study in Rochester Minnesota.  Diabetes. 1998;  37 405-412
• 4 Rossing P, Rossing K, Jacobsen P. Unchanged incidence of diabetic nephropathy in IDDM patients.  Diabetes. 1995;  44 739-743
• 5 Caprio S, Wong S, Alberti K GMM. Cardiovascular complications of diabetes.  Diabetologia. 1997;  40 B78-B82
• 6 Panzram G. Mortality and survival in Type 2 (non insulin dependent) diabetes mellitus.  Diabetologia. 1987;  30 123-131
• 7 Standl E, Balletshofer B, Dahl B, Weichenhain B, Stiegler H, Hörmann A, Holle R. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project.  Diabetologia. 1996;  39 1540-1545
• 8 Francis G S. ACE inhibition in cardiovascular disease.  N Engl J Med. 2000;  342 201-202
• 9 Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dageneais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.  N Engl J Med. 2000;  342 145-153
• 10 Pahor M, Psaty B M, Alderman M H, Applegate W B, Williamson J D, Furberg C D. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes.  Diab Care. 2000;  23 888-892
• 11 Szucs T, Schneeweiss A. Cilazapril: an overview of its efficacy and safety in hypertension.  Cardiology. 1992;  80 34-41
• 12 Nazzaro P, Manzari M, Merlo M, Triggiani R, Scarano A M, Lasciarrea A, Marella N, Pirelli A. Stress reactivity in responder and non-responder hypertensives treated with verapamil and enalapril.  Riv Eur Sci Med Pharmacol. 1995;  17 105-113
• 13 Valles P M, Matas S M, Bronsoms A J, Mate B G, Torguet E P, Mauri N JM. Quinapril ACE-inhibition effects on adrenergic parameters in moderate essential hypertension.  Kidney Int Suppl. 1996;  55 S104-106
• 14 Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.  J Clin Invest. 1990;  86 1343-1346
• 15 Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, Soubrier F. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels.  Am J Hum Genet. 1992;  51 197-205
• 16 Ruiz J, Blanche H, Cohen N, Velho G, Cambien F, Cohen D, Passa P, Froguel P. Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus.  Proc Natl Acad Sci. 1994;  91 3662-3665
• 17 Cambien F O, Poirier O, Lecerf L, Evans A, Cambou J-P, Arveiler D, Luc G, Bard J-M, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F. Deletion polymorphism in the gene for angiotensin converting enzyme is a potent risk factor for myocardial infarction.  Nature. 1992;  359 641-644
• 18 Fujisawa T, Ikegami H, Shen G Q, Yamato E, Takekawa K, Nagakawa Y, Hamada Y, Ueda H, Rakugi H, Higaki J. Angiotensin-I-converting enzyme gene polymorphism is associated with myocardial infarction, but not with retinopathy or nephropathy, in NIDDM.  Diabetes Care. 1995;  18 983-985
• 19 Lindpaintner L, Pfeffer M A, Kreutz R, Stampfer M J, Grodstein F, LaMotte F, Buring J, Hennekens C H. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease.  N Engl J Med. 1995;  332 706-711
• 20 Ribichini F, Steffenino G, Dellavalle A, Matullo G, Colajanni E, Camilla T, Vado A, Benetton G, Uslenghi E, Piazza A. Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme. A major risk factor and a marker of risk for coronary stent restenosis.  Circulation. 1998;  97 147-154
• 21 Ruiz J, Blanche H, James R W, Blatter-Garin M C, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P. Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes.  Lancet. 1995;  346 869-872
• 22 Antikainen M, Murtomäki S, Syvänne M, Pahlmann R, Tahvanainen E, Jauhiainen M, Frick M H, Ehnaholm C. The Gln-Arg 191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns.  J Clin Invest. 1996;  98 883-885
• 23 Odawara M, Tachi Y, Yamashita K. Paraoxonase polymorphism (Gln192Arg) is associated with coronary heart disease in Japanese non insulin dependent diabetes mellitus.  J Clin Endocrinol Metab. 1997;  82 2257-2260
• 24 Serrato M, Marian A J. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease.  J Clin Invest. 1995;  96 3005-3008
• 25 Kunkel G R, Graham J B, Fowlkes D M, Lord S T. Rsa I Polymorphism in von Willebrand factor (vWF) at codon 789.  Nucl Acid Res. 1990;  18 4961
• 26 Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F. Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes.  Biochem J. 1993;  290 33-34
• 27 Keavney B D, Dudley C R, Stratton I M, Holman R R, Matthews D R, Ratcliffe P J, Turner R C. UK prospective diabetes study (UKPDS) 14: association of angiotensin-converting enzyme insertion/deletion polymorphism with myocardial infarction in NIDDM.  Diabetologia. 1995;  38 948-952
• 28 The CONSENSUS Trial Study Group . Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative heart north Scandinavian enalapril survival study (CONSENSUS).  N Engl J Med. 1987;  316 1429-1435
• 29 The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.  N Engl J Med. 1991;  325 293-302
• 30 Montgomery H, Clarkson P, Barnard M, Bell J, Brynes A, Dollery C, Hajnal J, Hemingway H, Mercer D, Jarman P, Marshall R, Prasad K, Rayson M, Saeed N, Talmud P, Thomas L, Jubb M, World M, Humphries S. Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training.  Lancet. 1999;  353 541-545
• 31 Williams A G, Rayson M P, Jubb M, World M, Woods D R, Hayward M, Martin J, Humphries S E, Montgomery H E. The ACE gene and muscle performance.  Nature. 2000;  403 614
• 32 Keavney B, McKenzie C, Parish S, Palmer A, Clark S, Youngman L, Delephine M, Lathrop M, Peto R, Colins R  for the International Studies of Infarct Suvival (ISIS) Collaborators. Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls.  Lancet. 2000;  355 434-442
• 33 Friedl W, Krempler F, Paulweber B, Pichler M, Sandhofer F. A deletion polymorphism in the angiotensin converting enzyme gene is not associated with coronary heart disease in an Austrian population.  Atherosclerosis. 1995;  112 137-143
• 34 Pfohl M, Koch M, Prescod S, Haase K K, Häring H U, Karsch K R. Angiotensin-I-converting enzyme gene polymorphism, coronary artery disease and myocardial infarction. An angiographically controlled study.  Eur Heart J. 1999;  20 1318-1325
• 35 Arca M, Pannitteri G, Campagna F, Candeloro A, Montali A, Cantini R, Seccareccia F, Campa P P, Marino B, Ricci G. Angiotensin-converting enzyme gene polymorphism is not associated with coronary atherosclerosis and myocardial infarction in a sample of Italian patients.  Eur J Clin Invest. 1998;  28 485-490
• 36 Agerholm-Larsen B, Nordestgaard B G, Steffensen R, Sörensen T IA, Jensen G, Tybjaerg-Hansen A. ACE gene polymorphism: ischemic heart disease and longevity in 10 150 individuals.  Circulation. 1997;  95 2358-2367